Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
About This Bill
Committee
Latest Action · May 14, 2026
Referred to the House Committee on Energy and Commerce.
This resolution expresses the House of Representatives' support for policies that allow broad access to mifepristone, a medication used for abortion and miscarriage management. The resolution states that over 25 years of scientific evidence and hundreds of peer-reviewed studies demonstrate the drug is safe and effective, and argues that policies governing access to mifepristone should be based on this scientific evidence rather than political considerations. The resolution supports allowing mifepristone to be prescribed through telemedicine and dispensed by mail or at pharmacies, and emphasizes that current restrictions on the drug are more stringent than those applied to 99 percent of other prescription medications. The resolution also argues that expanding access to medication abortion is necessary to ensure equitable care for marginalized communities, including Black and Indigenous people, immigrants, people with lower incomes, rural residents, and LGBTQ+ individuals. As a sense-of-the-House resolution, this measure expresses the legislative body's position but does not enact new law or allocate funding.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.